New Study Identifies Tirzepatide as Most Effective GLP-1 for Weight Loss

A 2024 JAMA Internal Medicine study identifies tirzepatide as the most effective GLP-1 for weight loss, outperforming semaglutide in real-world clinical data.

By: AXL Media

Published: Mar 3, 2026, 11:24 AM EST

Source: People

Tirzepatide vs. Semaglutide: A Data-Driven Comparison

The study analyzed electronic health records from over 18,000 adults with overweight or obesity to determine which "miracle drug" delivers the best results in a typical clinical setting. The findings were stark: patients on tirzepatide were roughly three times more likely to achieve 15% weight loss within one year compared to those on semaglutide. Specifically, at the 12-month mark, the mean weight loss for tirzepatide users was 15.3%, while semaglutide users saw a mean loss of 8.3%. This gap highlights the increased potency of tirzepatide’s dual-action mechanism, which targets both GLP-1 and GIP receptors.

Strategic Insights for the 2026 Healthcare Market

This study has massive strategic implications for the North American pharmaceutical market as we move through 2026. While semaglutide has higher brand recognition due to the "Ozempic" cultural phenomenon, tirzepatide is increasingly becoming the preferred clinical choice for aggressive weight management. TRANSFORMATIVE ANALYSIS: In the United States and Canada, insurance providers are using this data to refine their "step therapy" protocols. As tirzepatide demonstrates superior efficacy, some health systems are beginning to prioritize it for patients with higher BMIs, despite the higher manufacturing complexity of dual-agonist drugs.

Understanding the Role of Dual Agonists

The primary reason for tirzepatide's superior performance lies in its "twincretin" nature. While traditional GLP-1 agonists like semaglutide mimic one gut hormone to slow digestion and signal fullness, tirzepatide mimics two. Paraphrasing the source, researchers noted that the addition of the GIP (glucose-dependent insulinotropic polypeptide) receptor agonist allows for more significant metabolic regulation. This dual approach not only suppresses appetite more effectively but may also improve how the body processes sugar and fat, leading to the "larger reductions in body weight" observed in the JAMA study.